This collection provides information about MAT specifically for health care providers. It includes a pocket guide from the Substance Abuse and Mental Health Services Administration with a checklist of steps for providers to take when evaluating and managing patients using MAT to treat opioid use disorder, a 2019 update on medications to treat OUD, Michigan’s provider guidelines for MAT, and an open-source journal article that considers whether patient specific characteristics should be considered when determining dosage for MAT.
Note: If you know of a resource we can include in this collection of information about MAT for health care providers, please let us know by visiting our call for submissions page.
Medication-Assisted Treatment of Opioid Use Disorder: Pocket Guide
Source: Substance Abuse and Mental Health Services Administration (SAMHSA)
This pocket guide from SAMHSA is written for health care providers prescribing medication assisted treatment (MAT) for opioid use disorder. The guide includes a checklist of steps providers should take during the patient
Update on Medications Used to Manage Opioid Use Disorder and Opioid Withdrawal
Source: Moretz, D.
This 2019 update on medications to treat opioid use disorder and opioid withdrawal provides information about extended release formulations of buprenorphine, reviews evidence for the effectiveness of lofexidene to treat withdrawal symptoms, and also includes a table with comparative costs of opioid use disorder pharmacological therapies.
Medication Assisted Treatment Guidelines for Opioid Use Disorders
Source: Michigan Department of Community Health - MAT Work Group
This 2014 guideline from the Michigan Department of Community Health provides an overview of addiction and opioid use disorder with information specifically about medication assisted treatment.
Pharmacogenomics-Guided Policy in Opioid Use Disorder Management: An Ethically-Diverse Case-Based Approach
Source: Earl B. Ettienne, et. al.
This article describes the case of an individual prescribed buprenorphine for opioid use disorder (OUD) who did not achieve treatment stability at the maximum dose allowed by the patient’s insurer of 24 mg daily.